Alteogen Inc. and Lynkogen Inc. announced that they have expanded the scope of their exclusive option agreement. In addition to the originally announced GLP-1 mimetic fusion proteins, Lynkogen will also acquire exclusive rights to FGF21 fusions, including dual function FGF21/GLP-1 mimetic fusion protein. Lynkogen and Alteogen will also continue to partner in exploring the feasibility of other novel dual function agents utilizing Alteogen’s proprietary NexP Fusion Technology platform. Lynkogen will seek to raise a Series A round to fund the development of these assets. NASH is poised to be the leading cause of liver transplants by 2020 and the market is projected to reach over USD 20 Billion by 2025. Despite a significant unmet need, there is currently no approved therapeutics available for patients with NASH.